Clinical Trial Update: A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion [Phase 4]

View source ↗

Summary

Phase 4 safety study of ibrutinib (Imbruvica) in Indian participants with chronic lymphocytic leukemia or mantle cell lymphoma who have received prior therapy o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Johnson & Johnson Private Limited | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell | Phase 4 | Status: COMPLETED | Results posted: 2024-05-21